کریسپر درمانی:خرید ثانویه
CRISPR Therapeutics: Buy The Secondary
The stock has shown bullish price action recently.
Wall Street’s reaction to the recent secondary offering appears favorable.
A major milestone was achieved when they submitted their CTA for CTX001 in β-thalassemia.
Preclinical data provides rationale for ushering the program forward and their CAR-T efforts should not be overlooked.
Readers who have done their due diligence and are interested in the story should purchase pilot positions in the near term.
Shares of CRISPR Therapeutics (CRSP) have risen by over 50% in the past three months.